Современные подходы к ведению детей с атипичным гемолитико-уремическим синдромом

Экспертами Союза педиатров России разработаны актуальные клинические рекомендации по оказанию медицинской помощи детям с атипичным гемолитико-уремическим синдромом (аГУС). аГУС — ультраредкое (орфанное) заболевание прогрессирующего течения, характеризующееся рецидивированием на протяжении всей жизни и представляющее собой потенциально жизнеугрожающее состояние. В статье подробно рассмотрены вопросы этиологии, патогенеза, классификации заболевания. Особое внимание уделено диагностике, дифференциальной диагностике и терапии аГУС, основанным на принципах доказательности.

1. Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390(10095):681-696. doi: https://doi.org/10.1016/S0140-6736(17)30062-4

2. Scheiring J, Andreoli SP, Zimmerhackl LB. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS). Pediatr Nephrol. 2008;23(10):1749-1760. doi: https://doi.org/10.1007/s00467-008-0935-6

3. BrocklebankV,WoodKM,KavanaghD.ThromboticMicroangiopathy and the Kidney. Clin J Am Soc Nephrol. 2018;13(2):300-317. doi: https://doi.org/10.2215/CJN.00620117

4. Shatzel JJ, Taylor JA. Syndromes of Thrombotic Microangiopathy. Med Clin North Am. 2017;101(2):395-415. doi: https://doi.org/10.1016/j.mcna.2016.09.010

5. Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol. 2014;36(4):399-420. doi: https://doi.org/10.1007/s00281-014-0416-x

6. Williams DM, Sreedhar SS, Mickell JJ, Chan JC. Acute kidney failure: a pediatric experience over 20 years. Arch Pediatr Adolesc Med. 2002;156(9):893-900. doi: https://doi.org/10.1001/archpedi.156.9.893

7. Joseph A, Cointe A, Mariani Kurkdjian P, et al. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel). 2020;12(2):67. doi: https://doi.org/10.3390/toxins12020067

8. Luara Sh. Gemolitiko-uremicheskii sindrom In: Paediatric nephrology: a textbook for medical practitioners. Leumann E, Tsygin AN, Sarkissian AA, eds. Moscow: Litterra Publishers; 2010. pp. 184-193. (In Russ).

9. Karpman D, Loos S, Tati R, Arvidsson I. Haemolytic uraemic syndrome. J Intern Med. 2017;281(2):123-148. doi: https://doi.org/10.1111/joim.12546

10. Blasco M, Guillen E, Quintana LF, et al. Thrombotic microangiopathies assessment: mind the complement. Clin Kidney J. 2020;14(4):1055-1066. doi: https://doi.org/10.1093/ckj/sfaa195

11. Arnold DM, Patriquin CJ, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017;189(4): E153-E159. doi: https://doi.org/10.1503/cmaj.160142

12. Sheerin NS, Glover E. Haemolytic uremic syndrome: diagnosis and management. F1000Res. 2019;8(F1000 Faculty Rev):1690. doi: https://doi.org/10.12688/f1000research.19957.1

13. Ariceta G. Hemolytic Uremic Syndrome. Curr Treat Options Peds. 2020;6(4):252-262. doi: https://doi.org/10.1007/s40746-020-00216-1

14. Goodship TH. Factor H genotype-phenotype correlations: Lessons from aHUS, MPGN II, and AMD. Kidney Int. 2006;70(1):12-13. doi: https://doi.org/10.1038/sj.ki.5001612

15. Jokiranta TS. HUS and atypical HUS. Blood. 2017;129(21):2847-2856. doi: https://doi.org/10.1182/blood-2016-11-709865

16. Sepulveda RA, Tagle R, Jara A. Atypical hemolytic uremic syndrome. Rev Med Chil. 2018;146(6):770-779. doi: https://doi.org/10.4067/s0034-98872018000600770

17. Nester CM, Barbour T, de Cordoba SR, et al. Atypical aHUS: State of the art. Mol Immunol. 2015;67(1):31-42. doi: https://doi.org/10.1016/j.molimm.2015.03.246

18. Noris M, Caprioli J, Bresin E, et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5(10):1844-1859. doi: https://doi.org/10.2215/CJN.02210310

19. Pineda GE, Rearte B, Todero MF, et al. Absence of inter-leukin-10 reduces progression of shiga toxin-induced hemolytic uremic syndrome. Clin Sci (Lond). 2021;135(3):575-588. doi: https://doi.org/10.1042/CS20200468

20. Campistol JM, Arias M, Ariceta G, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013;33(1):27-45. doi: https://doi.org/10.3265/Nefrologia.pre2012.Nov.11781

21. Yan K, Desai K, Gullapalli L, et al. Epidemiology of Atypical Hemolytic Uremic Syndrome: A Systematic Literature Review. Clin Epidemiol. 2020;12:295-305. doi: https://doi.org/10.2147/CLEP.S245642

22. Loirat C, Fakhouri F, Ariceta G, et al. HUS International. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31(1):15-39. doi: https://doi.org/10.1007/s00467-015-3076-8

23. Bayer G, von Tokarski F, Thoreau B, et al. Etiology and Outcomes of Thrombotic Microangiopathies. Clin J Am Soc Nephrol. 2019;14(4):557-566. doi: https://doi.org/10.2215/CJN.11470918

24. Bagga A, Khandelwal P, Mishra K, et al. Hemolytic uremic syndrome in a developing country: Consensus guidelines. Pediatr Nephrol. 2019;34(8):1465-1482. doi: https://doi.org/10.1007/s00467-019-04233-7

25. Aigner C, Schmidt A, Gaggl M, Sunder-Plassmann G. An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy. Clin Kidney J. 2019;12(3):333-337. doi: https://doi.org/10.1093/ckj/sfz040

26. Noris M, Remuzzi G. Cardiovascular complications in atypical haemolytic uraemic syndrome. Nat Rev Nephrol. 2014;10(3):174-180. doi: https://doi.org/10.1038/nrneph.2013.280

27. Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol. 2019;34(8):1337-1348. doi: https://doi.org/10.1007/s00467-018-4039-7

28. Sampedro Lopez A, Dominguez Moro B, Baltar Martin JM, et al. Ocular involvement in atypical hemolytic uremic syndrome. Arch Soc Esp Oftalmol. 2017;92(12):594-597. doi: https://doi.org/10.1016/j.oftal.2017.02.007

29. Ardissino G, Tel F, Testa S, et al. Skin involvement in atypical hemolytic uremic syndrome. Am J Kidney Dis. 2014;63(4):652-655. doi: https://doi.org/10.1053/j.ajkd.2013.09.020

30. Al-Ahmad M, Kharita L, Wannous H. Atypical hemolytic uremic syndrome with peripheral gangrene and homocysteinemia in a child. Oxf Med Case Reports. 2020;2020(7):omaa048. doi: https://doi.org/10.1093/omcr/omaa048

31. Scobell RR, Kaplan BS, Copelovitch L. New insights into the pathogenesis of Streptococcus pneumoniae-associated hemolytic uremic syndrome. Pediatr Nephrol. 2020;35(9):1585-1591. doi: https://doi.org/10.1007/s00467-019-04342-3

32. Holle J, Habbig S, Gratopp Д, et al. Complement activation in children with Streptococcus pneumoniae associated hemolytic uremic syndrome. Pediatr Nephrol. 2021;36(5):1311-1315. doi: https://doi.org/10.1007/s00467-021-04952-w

33. Bitzan M, AlKandari O, Whittemore B, Yin XL. Complement depletion and Coombs positivity in pneumococcal hemolytic uremic syndrome (pnHUS). Case series and plea to revisit an old pathogenetic concept. Int J Med Microbiol. 2018;308(8):1096-1104. doi: https://doi.org/10.1016/j.ijmm.2018.08.007

34. Koenig JC, Rutsch F, Bockmeyer C, et al. Nephrotic syndrome and thrombotic microangiopathy caused by cobalamin C deficiency. Pediatr Nephrol. 2015;30(7):1203-1206. doi: https://doi.org/10.1007/s00467-015-3110-x

35. Grange S, Bekri S, Artaud-Macari E, et al. Adult-onset renal thrombotic microangiopathy and pulmonary arterial hypertension in cobalamin C deficiency. Lancet. 2015;386(9997):1011-1012. doi: https://doi.org/10.1016/S0140-6736(15)00076-8

36. Rezolyutsiya ekspertnogo soveta po optimizatsii podkhodov k terapii atipich-nogo gemolitiko-uremicheskogo sindroma po itogam zasedani-ya 18 aprelya 2014 goda, g. Moskva. Nephrology and Dialysis. 2014;16(2):304-306. (In Russ).

37. Goodship TH, Cook HT, Fakhouri F, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int. 2017;91(3):539-551. doi: https://doi.org/10.1016/j.kint.2016.10.005

38. Kato H, Nangaku M, Hataya H, et al. Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol. 2016;20(4):536-543. doi: https://doi.org/10.1007/s10157-016-1276-6

39. Gillespie RS. Pediatric Hemolytic Uremic Syndrome Workup. In: Medscape. November 12, 2018. Available online: https://emedicine.medscape.com/article/982025-workup. Accessed on April 10, 2022.

40. Noris M, Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol. 2005;16(4):1035-1050. doi: https://doi.org/10.1681/ASN.2004100861

41. Walsh PR, Johnson S. Treatment and management of children with haemolytic uraemic syndrome. Arch Dis Child. 2018;103(3):285-291. doi: https://doi.org/10.1136/archdischild-2016-311377

42. Lee H, Kang E, Kang HG, et al. Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome. Korean J Intern Med. 2020;35(1):25-40. doi: https://doi.org/10.3904/kjim.2019.388

43. Hervent AS, Godefroid M, Cauwelier B, et al. Evaluation of schistocyte analysis by a novel automated digital cell morphology application. Int J Lab Hematol. 2015;37(5):588-596. doi: https://doi.org/10.1111/ijlh.12363

44. Loirat C, Sonsino E, Varga Moreno A, et al. Hemolytic-uremic syndrome: an analysis of the natural history and prognostic features. Acta Paediatr Scand. 1984;73(4):505-514. doi: https://doi.org/10.1111/j.1651-2227.1984.tb09962.x

45. Geerdink LM, Westra D, van Wijk JAE, et al. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol. 2012;27(8):1283-1291. doi: https://doi.org/10.1007/s00467-012-2131-y

46. Fremeaux-Bacchi V, Fakhouri F, Garnier A, et al. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8(4):554-562. doi: https://doi.org/10.2215/CJN.04760512

47. Mallett A, Hughes P, Szer J, et al. Atypical haemolytic uraemic syndrome treated with the complement inhibitor eculizumab: the experience of the Australian compassionate access cohort. Intern Med J. 2015;45(10):1054-1065. doi: https://doi.org/10.1111/imj.12864

48. Shimizu M, Inoue N, Kuroda M, et al. Serum ferritin as an indicator of the development of encephalopathy in entero-hemorrhagic Escherichia coli-induced hemolytic uremic syndrome. Clin Exp Nephrol. 2017;21(6):1083-1087. doi: https://doi.org/10.1007/s10157-017-1391-z

49. Cheong HI, Jo SK, Yoon SS, et al. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci. 2016;31(10):1516-1528. doi: https://doi.org/10.3346/jkms.2016.31.10.1516

50. Thurman JM. ComplementBiomarkersofHemolyticUremicSyndrome-If Not One Thing, Maybe Another. Mayo Clin Proc. 2018;93(10):1337-1339. doi: https://doi.org/10.1016/j.mayocp.2018.08.024

51. Westra D, Volokhina EB, van der Molen RG, et al. Serological and genetic complement alterations in infection-induced and complement-mediated hemolytic uremic syndrome. Pediatr Nephrol. 2017; 32(2):297-309. doi: https://doi.org/10.1007/s00467-016-3496-0

52. Loirat C., Noris M., Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2008; 23(11):1957-1972. doi: https://doi.org/10.1007/s00467-008-0872-4

53. Laurence J. Atypical hemolytic uremic syndrome (aHUS): making the diagnosis. Clin Adv Hematol Oncol. 2012;10(10 Suppl 17):1-12.

54. Erickson YO, Samia NI, Bedell B, et al. Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients. J Clin Apher. 2009;24(4):150-154. doi: https://doi.org/10.1002/jca.20205

55. Wada H, Matsumoto T, Suzuki K, et al. Differences and similarities between disseminated intravascular coagulation and thrombotic microangiopathy. Thromb J. 2018;16:14. doi: https://doi.org/10.1186/s12959-018-0168-2

56. Palma LMP, Sridharan M, Sethi S. Complement in Secondary Thrombotic Microangiopathy. Kidney Int Rep. 2021;6(1):11-23. doi: https://doi.org/10.1016/j.ekir.2020.10.009

57. Zini G, De Cristofaro R. Diagnostic Testing for Differential Diagnosis in Thrombotic Microangiopathies. Turk J Haematol. 2019;36(4):222-229. doi: https://doi.org/10.4274/tjh.galenos.2019.2019.0165

58. Iba T, Levy JH, Wada H, et al. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2019;17(2):415-419. doi: https://doi.org/10.1111/jth.14354

59. Harahsheh Y, Ho KM. Thromboelastometry and thromboelastography failed to detect hypercoagulability in thrombotic microangiopathy. Anaesth Intensive Care. 2016;44(4):520-521. doi: https://doi.org/10.1177/0310057X1604400417

60. Rigamonti D, Simonetti GD. Direct cardiac involvement in childhood hemolytic-uremic syndrome: case report and review of the literature. Eur J Pediatr. 2016;175(12):1927-1931. doi: https://doi.org/10.1007/s00431-016-2790-y

61. Thomas NJ, Messina JJ, DeBruin WJ, Carcillo JA. Cardiac failure in hemolytic uremic syndrome and rescue with extracorporeal life support. Pediatr Cardiol. 2005;26(1):104-106. doi: https://doi.org/10.1007/s00246-004-0708-3

62. Schaefer F, Ardissino G, Ariceta G, et al. Clinical and genetic predictors of atypical hemolytic uremic syndrome phenotype and outcome. Kidney Int. 2018;94(2):408-418. doi: https://doi.org/10.1016/j.kint.2018.02.029

63. Fitzpatrick MM, Shah V, Trompeter RS, et al. Long term renal outcome of childhood haemolytic uraemic syndrome. BMJ. 1991;303(6801): 489-492. doi: https://doi.org/10.1136/bmj.303.6801.489

64. Karmali MA, Petric M, Bielaszewska M. Evaluation of a microplate latex agglutination method (Verotox-F assay) for detecting and characterizing verotoxins (Shiga toxins) in Escherichia coli. J Clin Microbiol. 1999;37(2):396-399. doi: https://doi.org/10.1128/JCM.37.2.396-399.1999

65. Fox LC, Cohney SJ, Kausman JY, et al. Consensus opinion on diagnosis and management of thrombotic microangiopathy in Australia and New Zealand. Intern Med J. 2018;48(6):624-636. doi: https://doi.org/10.1111/imj.13804

66. Baumgartner MR, Horster F, Dionisi-Vici C, et al. Proposed guidelines for the diagnosis and management of methylmalonic and propionic acidemia. Orphanet J Rare Dis. 2014;9:130. doi: https://doi.org/10.1186/s13023-014-0130-8

67. Mikhailova SV, Zakharova EYu, Petrukhin AS. Neirometabolicheskie zabolevaniya u detei i podrostkov. Diagnostika i podkhody k lecheniyu. Moscow: Litterra; 2019. pp. 34-36. (In Russ).

68. Sharma AP, Greenberg CR, Prasad AN, Prasad C. Hemolytic uremic syndrome (HUS) secondary to cobalamin C (cblC) disorder. Pediatr Nephrol. 2007;22(12):2097-103. doi: https://doi.org/10.1007/s00467-007-0604-1

69. Chen M, Zhuang J, Yang J, et al. Atypical hemolytic uremic syndrome induced by CblC subtype of methylmalonic academia: A case report and literature review. Medicine (Baltimore). 2017;96(43):e8284. doi: https://doi.org/10.1097/MD.0000000000008284

70. Laurence J, Haller H, Mannucci PM, et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl. 11(11):2–15.

71. Raina R, Grewal MK, Radhakrishnan Y, et al. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis. 2019;12:183-204. doi: https://doi.org/10.2147/IJNRD.S215370

72. Ardissino G, Tel F, Sgarbanti M, et al. Complement functional tests for monitoring eculizumab treatment in patients with atypical hemolytic uremic syndrome: an update. Pediatr Nephrol. 2018;33(3):457-461. doi: https://doi.org/10.1007/s00467-017-3813-2

73. Gillespie RS. Pediatric Hemolytic Uremic Syndrome. In: Medscape. November 12, 2018. Available online: https://emedicine.medscape.com/article/982025-workup28. Accessed on April 13, 2022.

74. Proesmans W, Dhooge A, Van Dyck M, Van Geet C. Thrombophilia in childhood hemolytic uremic syndrome. Pediatr Nephrol. 2002;17(8):699-700. doi: https://doi.org/10.1007/s00467-002-0908-0

75. Ueda Y, Miwa T, Gullipalli D, et al. Blocking Properdin Prevents Complement-Mediated Hemolytic Uremic Syndrome and Systemic Thrombophilia. J Am Soc Nephrol. 2018;29(7):1928-1937. doi: https://doi.org/10.1681/ASN.2017121244

76. Pundziene B, Dobiliene D, Cerkauskiene R, et al. Longterm follow-up of children with typical hemolytic uremic syndrome. Medicina (Kaunas). 2015;51(3):146-151. doi: https://doi.org/10.1016/j.medici.2015.06.004

77. Togarsimalemath SK, Si-Mohammed A, Puraswani M, et al. Gastrointestinal pathogens in anti-FH antibody positive and negative Hemolytic Uremic Syndrome. Pediatr Res. 2018;84(1):118-124. doi: https://doi.org/10.1038/s41390-018-0009-9

78. Imataka G, Wake K, Suzuki M, et al. Acute encephalopathy associated with hemolytic uremic syndrome caused by Escherichia coli O157: Н7 and rotavirus infection. Eur Rev Med Pharmacol Sci. 2015;19(10):1842-1844.

79. Birlutiu V, Birlutiu RM. Haemolytic-uremic syndrome due to infection with adenovirus: A case report and literature review. Medicine (Baltimore). 2018;97(7):e9895. doi: https://doi.org/10.1097/MD.0000000000009895

80. Reising A, Hafer C, Hss M, et al. Ultrasound findings in ЕНЕС-associated hemolytic-uremic syndrome and their clinical relevance. Int Urol Nephrol. 2016;48(4):561-570. doi: https://doi.org/10.1007/s11255-015-1194-7

81. Abrams CM, Njano DR, Bagga B. Abdominal Pain in the Setting of Atypical Hemolytic Uremic Syndrome Caused by Streptococcus pneumoniae Pneumonia. Glob Pediatr Health. 2018;5:2333794X18762866. doi: https://doi.org/10.1177/2333794X18762866

82. Koehl B, Boyer O, Biebuyck-Gouge N, et al. Neurological involvement in a child with atypical hemolytic uremic syndrome. Pediatr Nephrol. 2010;25(12):2539-2542. doi: https://doi.org/10.1007/s00467-010-1606-y

83. Toldo I, Manara R, Cogo P, et al. Diffusion-weighted imaging findings in hemolytic uremic syndrome with central nervous system involvement. J Child Neurol. 2009;24(2):247-250. doi: https://doi.org/10.1177/0883073808323022

84. Eriksson KJ, Boyd SG, Tasker RC. Acute neurology and neurophysiology of haemolytic-uraemic syndrome. Arch Dis Child. 2001;84(5):434-435. doi: https://doi.org/10.1136/adc.84.5.434

85. Rindy LJ, Chambers AR. Bone Marrow Aspiration And Biopsy. Treasure Island (FL): StatPearls Publishing; 2021. Available online: https://www.ncbi.nlm.nih.gov/books/NBK559232. Accessed on April 13, 2022.

86. Bain BJ. Bone marrow aspiration. J Clin Pathol. 2001;54(9):657-663. doi: https://doi.org/10.1136/jcp.54.9.657

87. Thayu M, Chandler WL, Jelacic S, et al. Cardiac ischemia during hemolytic uremic syndrome. Pediatr Nephrol. 2003;18(3):286-289. doi: https://doi.org/10.1007/s00467-002-1039-3

88. Shpikalova IYu, Pankratenko TE, Emirova KhM, et al. Neurological involvement in patients with STEC-Associated Hemolytic Uremic Syndrome (STEC-HUS): modern aspects of pathogenesis, clinical features and treatment modalities (Review). Nephrology and Dialysis. 2014;16(3):328-338. (In Russ).

89. Balestracci A, Martin SM, Toledo I, et al. Dehydration at admission increased the need for dialysis in hemolytic uremic syndrome children. Pediatr Nephrol. 2012;27:1407-1410. doi: https://doi.org/10.1007/s00467-012-2158-0

90. Scully M, Cataland S, Coppo P, et al. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. J Thromb Haemost. 2017;15(2):312-322. doi: https://doi.org/10.1111/jth.13571

91. Campbell CM, Kahwash R. Will complement inhibition be the new target in treating COVID-19 related systemic thrombosis. Circulation. 2020;141(22):1739-1741. doi: https://doi.org/10.1161/CIRCULATI0NAHA.120.047419

92. Ramlall V, Thangaraj P, Meydan C, et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med. 2020;26(10):1609-1615. doi: https://doi.org/10.1038/s41591-020-1021-2

93. Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb Thrombolysis. 2021;51(3):657-662. doi: https://doi.org/10.1007/s11239-020-02297-z

94. Gillespie RS. Pediatric Hemolytic Uremic Syndrome Treatment & Management. In: Medscape. November 12, 2018. Available online: https://emedicine.medscape.com/article/982025-treatment. Accessed on April 13, 2022.

95. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl. 2012;2(1):1-138.

96. Bruyand M, Mariani-Kurkdjian P, Le Hello S, et al. Paediatric haemolytic uraemic syndrome related to Shiga toxin-producing Escherichia coli, an overview of 10 years of surveillance in France, 2007 to 2016. Euro Surveill. 2019;24(8):1800068. doi: https://doi.org/10.2807/1560-7917.ES.2019.24.8.1800068

97. Ito S, Hdaka Y, Inoue N, et al. Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol. 2019;23(1):112-121. doi: https://doi.org/10.1007/s10157-018-1610-2

98. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368(23):2169-2181. doi: https://doi.org/10.1056/NEJMoa1208981

99. Licht C, Greenbaum LA, Muus P, et al. Efficacy and safety of Eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87(5):1061-1073. doi: https://doi.org/10.1038/ki.2014.42

100. Krishnappa V, Gupta M, Elrifai M, et al. Atypical hemolytic uremic syndrome: a meta-analysis of case reports confirms the prevalence of genetic mutations and the shift of treatment regimens. Ther Apher Dial. 2018;22(2):178-188. doi: https://doi.org/10.1111/1744-9987.12641

101. Menne J, Greenbaum L, Licht C, et al. Long-term safety and effectiveness of eculizumab for patients with atypical haemolytic uraemic syndrome: outcomes from a prospective observational clinical trial. Nephrol Dial Transplant. 2017;32(Suppl_3):iii572-iii573. doi: https://doi.org/10.1093/ndt/gfx170.MP3931

102. Menne J, Delmas Y, Fakhouri F, et al. Eculizumab prevents thrombotic microangiopathy in patients with atypical hemolytic uremic syndrome in a long-term observational study. Clin Kidney J. 2018;12(2):196-205. doi: https://doi.org/10.1093/ckj/sfy035

103. Puraswani M, Khandelwal P, Saini Н, et al. Clinical and Immunological Profile of Anti-factor Н Antibody Associated Atypical Hemolytic Uremic Syndrome: A Nationwide Database. Front Immunol. 2019;10:1282. doi: https://doi.org/10.3389/fimmu.2019.01282

104. Boyer O, Balzamo E, Charbit M, et al. Pulse cyclophosphamide therapy and clinical remission in atypical hemolytic uremic syndrome with anti-complement factor Н autoantibodies. Am J Kidney Dis. 2010;55(5):923-927. doi: https://doi.org/10.1053/j.ajkd.2009.12.026

105. Niaudet P, Gillion Boyer O. Complement-mediated hemolytic uremic syndrome in children. In: UpToDate. Marth 03, 2022. Available online: https://www.uptodate.com/contents/complement-mediat-ed-hemolytic-uremic-syndrome-in-children?search=Complement-mediated%20hemolytic%20uremic%20syndrome%20in%20children&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1. Accessed on April 13, 2022.

106. Durey MA, Sinha A, Togarsimalemath SK, Bagga A. Anticomplement-factor H-associated glomerulopathies. Nat Rev Nephrol. 2016;12(9):563-578. doi: https://doi.org/10.1038/nrneph.2016.99

107. Sinha A, Gulati A, Saini S, et al. Indian HUS Registry. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014;85(5):1151-1160. doi: https://doi.org/10.1038/ki.2013.373

108. Fakhouri F, ment in atypical drome. Semin doi: https://doi.org/10.1053/j.seminhematol.2018.04.009

109. Kise T, Fukuyama S, Uehara M. Successful Treatment of Anti-Factor H Antibody-Associated Atypical Hemolytic Uremic Syndrome. Indian J Nephrol. 2020;30(1):35-38. doi: https://doi.org/10.4103/ijn.IJN_336_1

110. Государственный реестр лекарственных средств. Available online: https://grls.ros-minzdrav.ru. Accessed on April 13, 2022.

111. Fakhouri F, Fila M, Hummel A, et al. Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. Blood. 2021;137(18):2438–2449. doi: https://doi.org/10.1182/blood.2020009280

112. Winthrop KL, Mariette X, Silva JT, et al. ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors). Clin Microbiol Infect. 2018;24 Suppl 2:S21-S40. doi: https://doi.org/10.1016/j.cmi.2018.02.002

113. Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol. 2019;34(11):2261-2277. doi: https://doi.org/10.1007/s00467-018-4091-3

114. Resolution of the interdisciplinary council experts for prevention of severe infections in patients with genetic disorders of regulation of the complement system, receiving therapy with eculizumab. Epidemiology and Vaccinal Prevention. 2017;16(1):51-54. (In Russ).

115. Apicella M. Treatment and prevention of meningococcal infection. In: UpToDate. December 22, 2020. Available online: https://www.uptodate.com/contents/treatment-and-prevention-of-meningococcal-infection?sectionName=Patients%20receiving%20C5%20inhibitors&search=atypical%20HUS%20children&topicRef=-6084&anchor=H2536994243&source=see_link#H2536994243. Accessed on April 13, 2022.

116. Tanaka K, Fujita N, Hibino S. Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizum-ab: a report of two cases. CEN Case Rep. 2020;9(3):247-251. doi: https://doi.org/10.1007/s13730-020-00465-x

117. McNamara LA, Topaz N, Wang X, et al. High Risk for Invasive Meningococcal Disease Among Patients Receiving Eculizumab (Soliris) Despite Receipt of Meningococcal Vaccine. MMWR Morb Mortal Wkly Rep. 2017;66(27):734-737. doi: https://doi.org/10.15585/mmwr.mm6627e1

118. Molloy L. Preventing meningococcal disease in patients receiving Soliris. In: Healio. May 16, 2018. Available online: https://www.healio.com/news/infectious-disease/20180509/preventing-meningococ-cal-disease-in-patients-receiving-soliris. Accessed on April 13, 2022.

119. Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(RR-2):1-28.

120. American Academy of Pediatrics. Meningococcal infections. In: Kimberlin DW, Jackson MA, Long SS, Brady MT. Red Book. 20182021. Report of the Committee on Infectious Diseases. Itasca, IL: American Academy of Pediatrics; 2018. p. 550.

121. Krone M, Lam T-T, Vogel U, Claus H. Susceptibility of invasive Neisseria meningitidis strains isolated in Germany to azithromycin, an alternative agent for post-exposure prophylaxis. J Antimicrob Chemother. 2020;75(4):984-987. doi: https://doi.org/10.1093/jac/dkz535

122. Kozlovskaya NL, Prokopenko EI, Emirova KhM, Serikova SYu. Klinicheskie rekomendatsii po diagnostike i lecheniyu atipichnogo gemolitiko-uremicheskogo sindroma. Nephrology and Dialysis. 2015;17(3):242-264. (In Russ).

123. Macia M; de Alvaro Moreno F, Dutt T, et al. Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome. Clin Kidney J. 2017;10(3):310-319. doi: https://doi.org/10.1093/ckj/sfw115

124. Go RS, Winters JL, Leug N, et al. Thrombotic microangiopathy care pathway: a consensus statement for the Mayo Clinic complement alternative pathway - thrombotic microangiopathy (CAP-TMA) disease-oriented group. Mayo Clin Proc. 2016;91(9):1189-1211. doi: https://doi.org./10.1016/j.mayocp.2016.05.015

125. Menne J, Delmas Y, Fakhouri F, et al. Outcome in patients with atypical hemolytic uremic syndrome treated with Eculizumab in a long-term observational study. BMC Nephrology. 2019;20(1):125-137. doi: https://doi.org/10.1186/s12882-019-1314-1

126. Avila Bernabeu AI, Cavero Escribano T, Cao Vilarino M. Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era. Nephron. 2020;144(11):537-549. doi: https://doi.org/10.1159/000508920

127. Chaturvedi S, Dhaliwal N, Hussain S, et al. Outcomes of a clinician-directed protocol for discontinuation of complement inhibition therapy in atypical hemolytic uremic syndrome. Blood Adv. 2021;5(5):1504-1512. doi: https://doi.org/10.1182/bloodadvances.2020003175

128. Raina R, Krishnappa V, Blaha T, et al. Atypical Hemolytic-Uremic Syndrome: An Update on Pathophysiology, Diagnosis, and Treatment. Ther Apher Dial. 2019;23(1):4-21. doi: https://doi.org/10.1111/1744-9987.12763

129. Ariceta G, Besbas N, Johnson S, et al. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol. 2009;24(4):687-696. doi: https://doi.org/10.1007/s00467-008-0964-1

130. Filip C, Nicolescu A, Cinteza E, et al. Cardiovascular Complications of Hemolytic Uremic Syndrome in Children. Maedica (Bucur). 2020;15(3): 305-309. doi: https://doi.org/10.26574/maedica.2020.15.3.305

131. Gomez-Lado C, Martinon-Torres F, Alvarez-Moreno A, et al. Reversible posterior leukoencephalopathy syndrome: An infrequent complication in the course of haemolytic-uremic syndrome. Rev Neurol. 2007;44(8):475-478.

132. Dyck MV, Proesmans W. Renoprotection by ACE inhibitors after severe hemolytic uremic syndrome. Pediatr Nephrol. 2004;19(6):688-690. doi: https://doi.org/10.1007/s00467-004-1451-y

133. Caletti MG, Balestracci A, Missoni M, Vezzani C. Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome. Pediatr Nephrol. 2013;28(5):745-750. doi: https://doi.org/10.1007/s00467-012-2374-7

134. Noris M, Bresin E, Mele C, Remuzzi G. Genetic Atypical Hemolytic-Uremic Syndrome. 2007 Nov 16 [updated 2016 Jun 9]. In: GeneReviews® [Internet]. Adam MP, Ardinger HH, Pagon RA, et al., eds. Seattle (WA): University of Washington, Seattle; 1993-2021.

135. Matzke GR, Aronoff GR, Atkinson AJ Jr, et al. Drug dosing consideration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2011;80(11):1122-1137. doi: https://doi.org/10.1038/ki.2011.322

136. Smyth B, Jones C, Saunders J. Prescribing for patients on dialysis. Aust Prescr. 2016;39(1):21-24. doi: https://doi.org/10.18773/austprescr.2016.008

137. Lea-Henry TN, Carland JE, Stocker SL, et al. Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles. Clin J Am Soc Nephrol. 2018;13(7):1085-1095. doi: https://doi.org/10.2215/CJN.00340118

138. Roberts DM, Sevastos J, Carland JE, et al. Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens. Clin J Am Soc Nephrol. 2018;13(8):1254-1263. doi: https://doi.org/10.2215/CJN.05150418

139. Krid S, Roumenina LT, Beury D, et al. Renal transplantation under prophylactic eculizumab in atypical hemolytic uremic syndrome with CFH/CFHR1 hybrid protein. Am J Transplant. 2012;12(7):1938-1944. doi: https://doi.org/10.1111/j.1600-6143.2012.04051.x

140. Weitz M, Amon O, Bassler D, et al. Prophylactic eculizum-ab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26(8):1325-1329. doi: https://doi.org/10.1007/s00467-011-1879-9

141. Bresin E, Daina E, Noris M, et al. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: prognostic significance of genetic background. Clin J Am Soc Nephrol. 2006;1(1):88-99. doi: https://doi.org/10.2215/CJN.00050505

142. Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne). 2014;1:52. doi: https://doi.org/10.3389/fmed.2014.00052

143. Claes KJ, Massart A, Collard L, et al. Belgian consensus statement on the diagnosis and management of patients with atypical hemolytic uremic syndrome. Acta Clin Belg. 2018;73(1):80-89. doi: https://doi.org/10.1080/17843286.2017.1345185

144. Kaabak MM, Molchanova EA, Nesterenko IV, et al. Interdisciplinary expert council resolution. Kidney transplantation in patients with atypical hemolytic-uremic syndrome: clinical and organizational-methodical aspects of patient management. Clinical Nephrology. 2018;(3):8-14. (In Russ.) doi: https://doi.org/10.18565/nephrology.2018.3.8-14

145. Gonzalez Suarez ML, Thongprayoon C, Mao MA, et al. Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis. J Clin Med. 2019;8(7):919. doi: https://doi.org/10.3390/jcm8070919

146. Siedlecki AM, Isbel N, Vande Walle J, et al. Eculizumab use for kidney transplantation patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2018;4(3):434-446. doi: https://doi.org/10.1016/j.ekir.2018.11.010

147. Bonthuis M, Harambat J, Berard E, et al. Recovery of Kidney Function in Children Treated with Maintenance Dialysis. Clin J Am Soc Nephrol. 2018;13(10):1510-1516. doi: https://doi.org/10.2215/CJN.01500218